Understanding Pancreatic Cancer Treatment Resistance Using Patient-Derived Models
Core 2: Human Specimen and Organic Core (HSO Core)
['FUNDING_P01'] · SALK INSTITUTE FOR BIOLOGICAL STUDIES · NIH-11167622
This work helps us understand why pancreatic cancer treatments stop working by studying models made from patient tumors.
Quick facts
| Phase | ['FUNDING_P01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SALK INSTITUTE FOR BIOLOGICAL STUDIES (nih funded) |
| Locations | 1 site (La Jolla, UNITED STATES) |
| Trial ID | NIH-11167622 on ClinicalTrials.gov |
What this research studies
Patients with pancreatic cancer often find that their treatments become less effective over time. Our team is creating special 3D models, called organoids, directly from patient tumors to understand why this happens. These organoids act like miniature versions of the patient's tumor, allowing us to test new drug combinations and discover better ways to fight treatment resistance. We also use tumor slices and develop organoids from other models to explore how different cells interact within the tumor.
Who could benefit from this research
Good fit: This research focuses on understanding pancreatic ductal adenocarcinoma (PDA) and mechanisms of therapeutic resistance, making it relevant to patients diagnosed with this condition.
Not a fit: Patients without pancreatic ductal adenocarcinoma or those not experiencing treatment resistance would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new and more effective treatment strategies for patients with pancreatic cancer who have developed resistance to current therapies.
How similar studies have performed: The use of patient-derived organoids is a growing field, and similar approaches have shown promise in accurately reflecting patient tumor characteristics and drug responses.
Where this research is happening
La Jolla, UNITED STATES
- SALK INSTITUTE FOR BIOLOGICAL STUDIES — La Jolla, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: TIRIAC, HERVE — SALK INSTITUTE FOR BIOLOGICAL STUDIES
- Study coordinator: TIRIAC, HERVE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.